NCT02316171View on ClinicalTrials.gov

CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON)

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

January 16, 2015

Primary Completion Date

March 14, 2016

Study Completion Date

March 14, 2016

Conditions

Non-muscle Invasive Bladder Cancer

Interventions

BIOLOGICAL

CVA21

CAVATAK is a purified preparation of CVA21

DRUG

Mitomycin C

Chemotherapy

Trial Locations (1)

Unknown

University of Surrey, Guildford

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Viralytics

INDUSTRY

NCT02316171 - CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON) | Biotech Hunter | Biotech Hunter